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definitive RT, with or without concurrent chemotherapy, for head and 
neck cancer. Sixteen patients had FMISO PET scans in week 3 of RT 
and 14 completed a third scan upon completion of therapy. Maximum 
standard uptake values (SUVmax) and tumour-to-normal ratios (TNR) on 
the FMISO PET scans were measured as indictors of hypoxia. All 
patients underwent an 18Fluorodeoxyglucose (FDG) PET prior to 
commencing therapy and 14 had an FDG PET at 12 weeks post 
completion of RT. Median follow-up was 62 months with a minimum of 
58 months in surviving patients. 
Results: Twenty-seven FMISO avid lesions were detected. No local 
failures were observed in 14 lesions with an FMISO TNR 1.3 (61.5% vs. 
100%, p = 0.016). Overall survival (OS) at 5 years was poorer in 
patients with a FMISO TNR lesion of >1.3 (27.3% vs. 100%, p = 0.004) 
and a trend towards worse disease specific survival (DSS) (63.6% vs. 
100%, p = 0.12) was observed in this group. Complete resolution of 
FMISO uptake was seen in 14 patients, with 85% resolving before 
receiving 30 Gy. This was not associated with improved LC, DSS or OS 
nor was complete metabolic response on FDG PET, which occurred in 
71.4% of patients. FMISO SUVmax was not significantly associated with 
patient outcomes. 
Conclusions: Pre-radiotherapy FMISO PET is predictive for poor 
patient outcomes at 5 years, despite apparent disease response on 
serial functional imaging. FMISO PET has the potential utility for risk 
stratification and also provides valuable spatial information regarding 
patterns of failure and warrants further clinical evaluation. 
   
OC-0326   
Coregistration of 18F-FAZA- and 18F-FDG-PET in NSCLC 
V.R. Bollineni1, G.S.M.A. Kerner2, J. Pruim3, R.J.H.M. Steenbakkers1, 
M.J.B. Koole3, J. Widder1, H.J.M. Groen2, J.A. Langendijk1 
1University Medical Center Groningen / University of Groningen, 
Radiotherapy, Groningen, The Netherlands  
2University Medical Center Groningen / University of Groningen, 
Pulmonology, Groningen, The Netherlands  
3University Medical Center Groningen / University of Groningen, 
Nuclear Medicine and Molecular Imaging, Groningen, The Netherlands  
 
Purpose/Objective: Tumour hypoxia hampers the efficacy of 
radiotherapy (RT) due to increased radioresistance. Tumour hypoxia 
can be visualized by PET using hypoxia tracers like 18F-FAZA. However, 
previous studies showed that high 18F-FDG uptake is also associated 
with hypoxia. In this respect, the question arises as to whether 18F-
FDG and 18F-FAZA uptake show high spatial correlation or provide 
complimentary information that can be used for RT treatment 
optimization strategies. Therefore, the aim of the present study was: 
(1) to quantify tumour hypoxia using 18F-FAZA-PET,and: (2) to 
investigate the spatial 18F-FAZA-uptake in relation to 18F-FDG-uptake. 
Materials and Methods: Eleven patients with stage III or IV NSCLC 
underwent 18F-FDG and 18F-FAZA-PETprior to chemo(radio)therapy. To 
depict 18F-FDG uptake, the maximum standardized uptake value 
(SUVmax) was used, whereas to quantify hypoxia, the tumor-to-
background ratio (T/B ratio) was used and the percentage of tumour 
exhibiting a fractional hypoxic volume (FHV) > 1.4 was assessed. Both 
PET scans were made in treatment position. To enable spatial 
correlation between 18F-FDG and 18F-FAZA scans, voxel based analysis 
of respective uptake values employing deformable image registration 
was performed. 
Results: All eleven patients showed clear uptake of 18F-FAZA in the 
primary tumour. No significant correlation was observed between 18F-
FDG-SUVmax and the 18F-FAZA-T/B ratio. The median FHV 1.4 was 
48.4% (range5.0-91.5). Neither lesion size nor 18F-FDG SUVmax 
significantly correlated with FHV, whereas a significant correlation 
between 18F-FDGSUVmax and lesion size (r = 0.82; P = 0.002) was 
observed. The pattern of uptake of 18F-FAZA varied widely among 
tumours and was more heterogeneous compared to uptake of 18F-FDG, 
resulting in different spatial distribution patterns (Fig 1). Inmost 
patients, there was a trend towards higher 18F-FAZA-uptake with 
increasing uptake of 18F-FDG. In some patients (panel A), well 
demarcated high uptake areas of 18F-FAZA were observed within 
metabolically active tumour volumes, indicating local hypoxic 
subareas in tumours with high metabolic activity. In other patients, 
18F-FAZA and 18F-FDG were more diffuse and did not correlate at all 
(panel B), indicating a more heterogeneous distribution of hypoxia 
throughout the entire tumour. 
 
Conclusions: 18F-FDG and 18F-FAZA-PETdata provide independent 
information about tumor metabolism. Addition of 18F-FAZA-PET to 18F-
FDG-PET imaging may direct the choice of hypoxia-directed RT 
treatment planning in NSCLC. 
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Purpose/Objective: FDG based metrics of the primary tumor at 
baseline PET images have been found predictive for overall survival in 
NSCLC patients. In this study the predictive power of advanced 
metabolic metrics derived from baseline PET images were compared 
against those already widely used, as maximum and mean uptake, and 
GTV. With this approach we aim to improve the existing predictors of 
outcome, allowing the implementation of decision support-based 
individualized care systems (www.predictcancer.org). 
Materials and Methods: In the context of a prospective study 
(NCT01302626), 197 NSCLC patients, stages I-III, treated with curative 
intent were included. Each patient underwent a precalibrated PET-CT 
scan before radiotherapy treatment. Primary GTV was delineated on 
CT by an experienced oncologist. PET images were normalized for SUV 
prior to analysis. We derived mean and maximum SUV, GTV and a set 
of metabolic features, quantified by an Intensity-Volume Histogram 
that summarizes into a single curve the spatial relation of tumor 
volume and SUV (Figure1): 
- Absolute/RelativeVolume above Absolute Intensity threshold – AVAI 
and RVAI 
- Absolute/RelativeVolume above Relative Intensity threshold – AVRI 
and RVRI 
- AbsoluteIntensity above Relative Volume threshold – AIRV 
AVAI and RVAI are built in steps of 0.5 (SUV) up to the maximum 
uptake (Figure 1B). Curves regarding relative quantities are built in 
steps of 10% (Figure 1 A and C). 
A Cox Proportional Hazard Regression was performed for overall 
survival. Performance was evaluated by the Concordance Index 
(probability of concordance between predicted and observed survival 
based on pairs of individuals: C-index). The proportional hazards 
assumption was checked by the Scaled Schoenfeld residuals by 
entering interaction terms with (log)time in the model. All statistical 
methods were applied with R (version 2.15.0). 
 
 
2nd ESTRO Forum 2013  S127 
	
 
Results: The median survival time was 1.82 years (95% CI – 1.57; 
2.06). A univariable analysis was performed for SUV descriptors and 
metabolic features. Results for the statistically significant metabolic 
features (p-value<0.05) are shown in Table 1. 
AVAI of 0.5 and 1, and AVRI of 10% showed a high correlation (Pearson 
correlation = 0.999,0.992 and 0.995) with GTV. 
Both RVRI of 80% and 90% (Pearson correlation =0.888) revealed a 
good prognostic value, outperforming the SUV descriptors. 
  
Conclusions: We investigated new approaches based on metabolic 
metrics derived from baseline PET images to analyze survival in NSCLC 
patients. AVAIof 0.5 and 1, and AVRI of 10% are a surrogate of tumor 
volume: highly correlated (≈1) with GTV and exhibiting identical 
performance. Metabolic features regarding portion of tumor above 
higher uptakes outperformed the most commonly used SUV metrics, 
maximum and mean. Currently, further investigation is ongoing by 
adding new patients to the analysis and applying results to an external 
dataset. 
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Purpose/Objective: SBRT for early stage non-small cell lung cancer is 
increasingly applied by many centres. Therefore, FDG-PET/CT is 
widely accepted as mandatory pre-treatment staging procedure, 
however, its timing is not standardised. In patients with locally 
advanced NSCLC, a high rate of tumou rgrowth and disease 
progression has been demonstrated when repeating the FDG-PET/CT 
during the SBRT planning phase accounting to about 30% upstaging 
probability within three weeks. The aim of this study was to 
investigate the FDG-PET/CT progression rate prior to SBRT. 
Materials and Methods: Nineteen consecutive early stage NSCLC 
patients referred for SBRT to the University Hospital Freiburg between 
08/2008 and 08/2011 were retrospectively analysed. All patients had 
already undergone an FDG-PET/CT scan at the time of referral and 
underwent a second FDG PET/CT for radiation planning purposes. All 
scans were analysed by two investigators blinded for treatment 
outcome regarding: availability of scan, tumour size and thus clinical 
T-stage, maximum standardized uptake value (SUVmax) in the tumour, 
additional FDG uptake in hilar/mediastinal lymph nodes (cN1/2) or at 
distant sites (cM1a/b). Progressive disease (>25% increase of tumour 
diameter on CT or >25% increase in SUVmax) and the time-interval 
between both imaging modalities were related to overall survival. 
Results: Median time interval between the diagnostic and planning 
FDG-PET/CT scan was 43 days (range: 22-140 days). After the planning 
FDG-PET/CT, 3/19 (15.8%) patients were not amenable for SBRT 
anymore due to diagnosis of nodal metastases (interscan interval: 22, 
51, and 95 days, respectively). No patients were found to have distant 
metastases. In the remaining 16 patients, no additional lesions were 
found, but one patient had progression in tumour diameter and two in 
SUVmax values. Notwithstanding, the lesions were still eligible for 
SBRT. Overall, upstaging occurred in 6/19 (31.6%) of patients, all but 
one with an interscan interval of more than 43 days (average 60 days, 
range 22-95 days). Overall, the upstaging probability with an interscan 
interval of less than 3 weeks was 0%. Furthermore, an SUVmax above 
median (9.50) on the diagnostic FDG-PET/CT scan was of borderline 
significance(p=0.06) for overall survival. 
Conclusions: In patients scheduled for SBRT, the rate of tumour 
growth and disease progression seen by repeated FDG-PET/CT was 
lower as compared to the situation in locally advanced disease. 
However, due to the risk of undertreatment of nodal progression in 
15.8% of cases, a timely scheduling of pre-treatment staging FDG-
PET/CT is recommended.  
 
 SYMPOSIUM: IMAGE-BASED ASSESSMENT OF THE 
RESPONSE OF NORMAL TISSUES TO RT  
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Radiation therapy (RT) is a major treatment modality for brain 
tumors.  As combining radiation therapy with chemotherapy and 
molecular targeted therapy is improving survival, neurotoxicity, 
including cognitive function decline and normal tissue necrosis, 
becomes an issue of quality of life.   Clinical symptoms and cognitive 
decline usually occur delayed or late as weeks, months or even years 
after the completion of RT. The clinical outcome ranges from mild, 
reversible damage to irreversible injury.  In the past, efforts to 
develop models to estimate the likelihood of developing radiation-
induced neurotoxicity have been primarily based on the planned 
radiation dose distribution, dose fraction size, and dose volume. 
These analyses have demonstrated their usefulness for permitting the 
safe delivery of higher doses of radiation than have previously been 
possible.  However, there is a broad range of individual patient 
sensitivity that is not reflected by predictions made solely based on 
the physical dose distribution or general clinical features.   If 
individual patient response to radiation could be better estimated 
before or during a course of treatment, it would permit higher doses 
of radiation to be delivered safely to the tumors of patients who is 
relatively radiation resistant, thus prolonging survival without 
increasing complications.   It would be valuable to identify 
biomarkers, including those derived from in vivo imaging, for early 
assessment of individual sensitivity to radiation and prediction of 
delayed and late neurotoxicity. Such biomarkers might provide an 
opportunity to individualize the dose of RT.  Our group has been 
conducting active research in this area.  We have used diffusion tensor 
(DTI) and dynamic contrast enhanced (DCE) MRI to assess individual 
and brain structural sensitivity to radiation.  Structural-variation in 
sensitivity to radiation may be related to the selective cognitive 
decline after brain irradiation.   Our results indicate that combining 
the early changes in the DTI and DCE indices of brain functional 
structures with doses has the potential to improve the prediction of 
delayed or late cognitive decline and/or brain tissue necrosis. 
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Radiation-induced lung toxicity (RILT) is one of the main dose-limiting 
factors in lung cancer treatment. It usually occurs within 3-6 months 
after the start of (chemo)radiotherapy and manifests itself with 
dyspnea, cough and fever. While the delivered dose to the lung is the 
primary cause of lung damage, different patients exhibit different 
susceptibility. In fact, only about 15%-25% of all lung cancer patients 
develop serious dyspnea problems (grade >=2 according to the 
Common Toxicity Criteria (CTC)), despite receiving a similar mean 
lung dose (15-20 Gy) as the rest of patients. It is therefore likely that 
other determinants, including clinical, dosimetric and tumor-related 
features, contribute to the observed individual susceptibility to lung 
damage. Since the heart and the lung form the interrelated 
